Table 2. Adjusted RI with 95% CIs of admissions with myocarditis in SUS using the SCCS analysis (adjusted for time period (4 weekly period)) in risk intervals after a COVID-19 vaccine or after a positive SARS-CoV-2 test stratified by age group and gender.
| Admissions (SUS dataset) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ages 16–39, n = 765 | Ages 40+, n = 1,134 | |||||||||
| Vaccination status | Interval (days) | Case count | Person years | RI (95% CI) | p-Value | Case count | Person years | RI (95% CI) | p-Value | |
| Baseline | 486 | 544 | 823 | 801.3 | ||||||
| ChAdOx1-S | Dose 1 | 0 to 6 | 9 | 2.2 | 5.23 (2.48, 11.01) | <0.001 | 11 | 7.8 | 1.45 (0.78, 2.71) | 0.238 |
| 7 to 13 | n < 2 | 2.4 | 9 | 8.9 | 0.98 (0.5, 1.93) | 0.955 | ||||
| Dose 2 | 0 to 6 | 2 | 2.6 | 1.01 (0.25, 4.13) | 0.991 | 7 | 12.5 | 0.53 (0.25, 1.12) | 0.097 | |
| 7 to 13 | 6 | 2.6 | 2.88 (1.25, 6.65) | 0.013 | 7 | 12.4 | 0.53 (0.25, 1.13) | 0.101 | ||
| BNT162b2 | Dose 1 | 0 to 6 | 18 | 9 | 2.23 (1.37, 3.63) | 0.001 | 5 | 2.3 | 2.01 (0.78, 5.2) | 0.151 |
| 7 to 13 | 14 | 9.2 | 1.62 (0.94, 2.79) | 0.084 | 3 | 2.8 | 1.03 (0.32, 3.3) | 0.965 | ||
| Dose 2 | 0 to 6 | 40 | 8 | 5.34 (3.81, 7.48) | <0.001 | 6 | 7.2 | 0.79 (0.35, 1.8) | 0.578 | |
| 7 to 13 | 17 | 7.9 | 2.25 (1.37, 3.68) | 0.001 | 5 | 7.2 | 0.67 (0.27, 1.62) | 0.37 | ||
| Booster | 0 to 6 | 17 | 3.5 | 4.38 (2.59, 7.38) | <0.001 | 22 | 13.2 | 1.5 (0.97, 2.33) | 0.07 | |
| 7 to 13 | 6 | 3.3 | 1.65 (0.72, 3.78) | 0.237 | 24 | 13.1 | 1.62 (1.06, 2.47) | 0.025 | ||
| mRNA-1273 | Dose 1 | 0 to 6 | 8 | 1.8 | 8.69 (4.01, 18.81) | <0.001 | 2 | 0.3 | 7.02 (1.53, 32.23) | 0.012 |
| 7 to 13 | n < 2 | 1.8 | n < 2 | 0.3 | ||||||
| Dose 2 | 0 to 6 | 38 | 1.4 | 56.48 (33.95, 93.97) | <0.001 | n < 2 | 0.2 | |||
| 7 to 13 | n < 2 | 1.4 | n < 2 | 0.2 | ||||||
| Booster | 0 to 6 | 11 | 1.4 | 7.88 (4.02, 15.44) | <0.001 | 3 | 2.8 | 0.88 (0.28, 2.8) | 0.827 | |
| 7 to 13 | n < 2 | 1.4 | 5 | 2.8 | 1.49 (0.6, 3.69) | 0.39 | ||||
| COVID infection test day 0 | 10 | 1.1 | 8.23 (4.34, 15.6) | <0.001 | 20 | 0.9 | 25.6 (16.09, 40.73) | <0.001 | ||
| Post COVID infection: 1–27d | 49 | 28.7 | 1.67 (1.22, 2.28) | <0.001 | 72 | 24 | 3.64 (2.76, 4.81) | <0.001 | ||
| All 16+ year olds: males, n = 1,194 | All 16+ year olds: females, n = 721 | |||||||||
| Vaccination status | Interval (days) | Case count | Person years | RI (95% CI) | p-Value | Case count | Person years | RI (95% CI) | p-Value | |
| Baseline | 792 | 844.7 | 523 | 513.2 | ||||||
| ChAdOx1-S | Dose 1 | 0 to 6 | 11 | 6.3 | 2.01 (1.08, 3.76) | 0.028 | 9 | 3.7 | 2.75 (1.35, 5.62) | 0.006 |
| 7 to 13 | 6 | 6.9 | 0.97 (0.43, 2.21) | 0.941 | 4 | 4.4 | 1.05 (0.38, 2.89) | 0.92 | ||
| Dose 2 | 0 to 6 | 6 | 8.9 | 0.79 (0.35, 1.78) | 0.563 | 3 | 6.2 | 0.5 (0.16, 1.58) | 0.239 | |
| 7 to 13 | 10 | 8.9 | 1.32 (0.7, 2.49) | 0.398 | 3 | 6.2 | 0.49 (0.16, 1.54) | 0.221 | ||
| BNT162b2 | Dose 1 | 0 to 6 | 16 | 8.5 | 2.04 (1.22, 3.42) | 0.006 | 8 | 3.2 | 2.62 (1.28, 5.36) | 0.009 |
| 7 to 13 | 13 | 8.9 | 1.59 (0.91, 2.78) | 0.105 | 7 | 3.4 | 1.9 (0.88, 4.1) | 0.103 | ||
| Dose 2 | 0 to 6 | 40 | 9.7 | 4.42 (3.18, 6.14) | <0.001 | 8 | 5.6 | 1.6 (0.78, 3.27) | 0.196 | |
| 7 to 13 | 16 | 9.6 | 1.78 (1.08, 2.94) | 0.025 | 6 | 5.6 | 1.18 (0.52, 2.68) | 0.685 | ||
| Booster | 0 to 6 | 22 | 9.4 | 2.01 (1.29, 3.11) | 0.002 | 17 | 7.3 | 2 (1.21, 3.3) | 0.007 | |
| 7 to 13 | 18 | 9.2 | 1.64 (1.01, 2.65) | 0.044 | 12 | 7.2 | 1.45 (0.8, 2.61) | 0.219 | ||
| mRNA-1273 | Dose 1 | 0 to 6 | 9 | 1.7 | 10.48 (5.02, 21.87) | <0.001 | n < 2 | 0.4 | ||
| 7 to 13 | n < 2 | 1.7 | n < 2 | 0.4 | ||||||
| Dose 2 | 0 to 6 | 35 | 1.3 | 58.24 (34.78, 97.52) | <0.001 | 4 | 0.2 | 23.26 (6.68, 81.06) | <0.001 | |
| 7 to 13 | n < 2 | 1.3 | n < 2 | 0.2 | ||||||
| Booster | 0 to 6 | 12 | 2.7 | 3.8 (2.06, 7.01) | <0.001 | 2 | 1.5 | 1.11 (0.27, 4.61) | 0.882 | |
| 7 to 13 | 3 | 2.7 | 0.99 (0.31, 3.15) | 0.99 | 3 | 1.4 | 1.72 (0.53, 5.56) | 0.363 | ||
| COVID infection test day 0 | 21 | 1.3 | 17.19 (10.98, 26.89) | <0.001 | 10 | 0.8 | 13.31 (6.99, 25.32) | <0.001 | ||
| Post COVID infection: 1–27d | 76 | 32.8 | 2.5 (1.93, 3.24) | <0.001 | 47 | 20.6 | 2.47 (1.77, 3.45) | <0.001 | ||
CI, confidence interval; COVID-19, Coronavirus Disease 2019; RI, relative incidence; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; SCCS, self-controlled case series; SUS, Secondary Uses Service.